Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302

May 14, 2012

by Sophiris Bio News Release

In: Posted Date, Publications, Published Date

Article published on November 24, 2011
Samuel Denmeade et al.

Background: PRX302 is a prostate specific antigen (PSA)–activated pore-forming protein toxin under development as a targeted approach for improving lowerurinary tract symptoms (LUTS) caused by

Read more